Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

67.050
+3.2505.09%
Volume:910.41K
Turnover:60.03M
Market Cap:36.41B
PE:44.42
High:67.850
Open:65.000
Low:63.850
Close:63.800
52wk High:92.000
52wk Low:18.600
Shares:543.00M
HK Float Shares:346.07M
Volume Ratio:0.75
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.510
ROE:27.54%
ROA:4.97%
PB:9.45
PE(LYR):44.42
PS:5.56

Loading ...

Goldman Sachs: Mainland Healthcare Sector Returns to Hinge on Data and Earnings Visibility This Year, CDMO Firms Favored

Stock News
·
8 hours ago

HENLIUS Shares Climb Over 5% on Licensing Deal with Eisai for Japan Rights

Stock News
·
Feb 06

Eisai and Henlius Enter Into Exclusive Commercial License Agreement for Anti-Pd-1 Antibody Serplulimab in Japan

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech Inc - Plans 2026 Application for Es-Sclc in Japan

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech (2696) and Eisai Sign License Agreement for HANSIZHUANG in Japan

Bulletin Express
·
Feb 05

Fosun Pharma's Subsidiary Henlius Enters Licensing Agreement with Eisai for Cancer Treatment

Stock News
·
Feb 05

Shanghai Henlius Biotech schließt Lizenzvereinbarung mit Eisai für Hansizhuang in Japan

Reuters
·
Feb 05

Shanghai Henlius Biotech - Granted Eisai Co License to Develop, Manufacture & Commercialise Hansizhuang

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech - Eisai to Pay Henlius $75 Mln Upfront Fee, Upon Execution of License Agreement

THOMSON REUTERS
·
Feb 05

BRIEF-Fosun Pharma Says Henlius Signs Licensing Agreement With Eisai

Reuters
·
Feb 05

Shanghai Fosun Pharmaceutical Says Henlius Biotech Signs Licensing Agreement With Eisai

THOMSON REUTERS
·
Feb 05

Shanghai Henlius Biotech (02696) Updates on Conversion of 182.65 Million Unlisted Shares into H Shares

Bulletin Express
·
Feb 04

Shanghai Henlius Biotech (2696) Announces Completion of H Share Full Circulation

Bulletin Express
·
Feb 04

HENLIUS (02696) Finalizes Full Circulation of H Shares

Stock News
·
Feb 04

Hong Kong Stock Movement | HENLIUS (02696) Rises Nearly 5% in Early Session as HLX22 Head-to-Head Trial with Keytruda for Gastric Cancer Holds Successful US Investigator Meeting

Stock News
·
Feb 03

BUZZ-Shanghai Henlius jumps most in 3-1/2 months on tumour drug trial approval

Reuters
·
Jan 28

Hong Kong Stock Movement | HENLIUS (02696) Rises Over 4% in Early Trading as HLX43 Combination Therapy Receives NMPA Approval for Clinical Trials

Stock News
·
Jan 28

Shanghai Henlius Receives Chinese Regulatory Nod to Begin Trials of HLX43 in Solid Tumors

MT Newswires Live
·
Jan 27

BRIEF-Shanghai Henlius Biotech Says Application For Clinical Trial Of HLX43 For Injection Approved

Reuters
·
Jan 27

Shanghai Henlius Biotech (2696) Obtains NMPA Approval for HLX43 Combination Therapy Trial in Advanced Solid Tumors

Bulletin Express
·
Jan 27